Skip to content
CIFAR header logo
fr
menu_mobile_logo_alt
  • Our Impact
    • Why CIFAR?
    • Impact Clusters
    • News
    • CIFAR Strategy
    • Nurturing a Resilient Earth
    • AI Impact
    • Donor Impact
    • CIFAR 40
  • Events
    • Public Events
    • Invitation-only Meetings
  • Programs
    • Research Programs
    • Pan-Canadian AI Strategy
    • Next Generation Initiatives
  • People
    • Fellows & Advisors
    • CIFAR Azrieli Global Scholars
    • Canada CIFAR AI Chairs
    • AI Strategy Leadership
    • Solution Network Members
    • Leadership
    • Staff Directory
  • Support Us
  • About
    • Our Story
    • Awards
    • Partnerships
    • Publications & Reports
    • Careers
    • Equity, Diversity & Inclusion
    • Statement on Institutional Neutrality
    • Research Security
  • fr
President's Message

Immediate action on COVID-19

By: Alan Bernstein
24 Mar, 2020
March 24, 2020
Microscopic

We need science now, more than ever. We need it because a foundation of science, built over decades, underlies the current medical and public health responses to COVID-19.

Dear Friends of CIFAR,

In these challenging times, I hope you are keeping safe and well. While social distancing has become the new normal, I am glad to see people coming together in creative ways to support each other. Strong communities are what will get us through this.

At CIFAR, the health and safety of our staff, donors, volunteers and community of researchers is our primary concern. All of our staff members are currently working from home and will continue to do so until public health officials announce it is safe to reconvene.

But the distance hasn’t slowed us down. CIFAR is taking immediate action in the global response to COVID-19. We are:

  • Working with governments to provide advice on artificial intelligence (AI) applied to health research and development related to COVID-19. This includes an international virtual meeting of over 70 top scientists to explore how AI might accelerate key approaches to ending this pandemic faster. Attendees included:
    • AI researchers

    • Public health officials

    • Clinical epidemiologists

    • Virologists

    • Vaccine developers

    • Drug developers

    • Mathematical modellers

    • Representatives from the WHO (World Health Organization)

    • Harold Varmus, Nobel Laureate and former director of the National Institutes of Health

    • Mona Nemer, Canada’s Chief Science Advisor

    • Representatives from the Gates Foundation and Wellcome Trust

  • Launching funding for collaborative research projects on AI and COVID-19 through CIFAR Catalyst Grants.

  • Convening interdisciplinary groups of experts who can work together on relevant research collaborations.

We are doing everything we can to mobilize CIFAR’s global community of experts in ways that help to advance what we know about — and what we can do about — this global pandemic. More information about these efforts is available at cifar.ca.

We need science now, more than ever. We need it because a foundation of science, built over decades, underlies the current medical and public health responses to COVID-19.

When Geoffrey Hinton, Yann LeCun, and Yoshua Bengio developed artificial neural networks, they did not plan for the technology to kickstart a multi-billion dollar global industry. Or that the technology would be used by Toronto-based company BlueDot years later to predict the emergence of a new virus in Wuhan.

The tests for COVID-19, developed in Germany, distributed by the World Health Organization, and deployed around the world to understand the extent of this outbreak, rely on the polymerase chain reaction. When Kary Mullis developed this technique, a discovery for which he shared the 1993 Nobel Prize in Chemistry with Canadian Michael Smith, how could he know that it would be the basis of crucial widespread testing for a deadly virus decades later?

We never know exactly which discoveries will find application in the future and what those applications will be. But we know some will. That’s why investment in research and the long-term commitment that CIFAR provides its research programs is so important. Extraordinary minds, working together, with sustained commitment and the freedom to dream big can change the world. CIFAR creates the space for that to happen.

Our support of a global scientific community that can tackle the immediate challenges facing humanity today, while also pursuing the long-term, fundamental questions that will shape our world for decades to come, is vitally important, now more than ever.

The world needs CIFAR. And CIFAR needs you. Thank you for your ongoing support.

DR. ALAN BERNSTEIN, O.C., OOnt., PhD, FRSC/MSRC
President & CEO, CIFAR

  • Follow Us

Related Articles

  • New program provides expert AI advice for policymakers
    April 30, 2025
  • Strengthening Canada’s AI talent ecosystem
    April 16, 2025
  • Humans & the Microbiome: Educational Modules for Public Health Professionals
    April 10, 2025
  • The value of community engagement in AI deployment
    March 31, 2025

Support Us

The Canadian Institute for Advanced Research (CIFAR) is a globally influential research organization proudly based in Canada. We mobilize the world’s most brilliant people across disciplines and at all career stages to advance transformative knowledge and solve humanity’s biggest problems, together. We are supported by the governments of Canada, Alberta and Québec, as well as Canadian and international foundations, individuals, corporations and partner organizations.

Donate Now
CIFAR footer logo

MaRS Centre, West Tower
661 University Ave., Suite 505
Toronto, ON M5G 1M1 Canada

Contact Us
Media
Careers
Accessibility Policies
Supporters
Financial Reports
Subscribe

  • © Copyright 2025 CIFAR. All Rights Reserved.
  • Charitable Registration Number: 11921 9251 RR0001
  • Terms of Use
  • Privacy
  • Sitemap

Subscribe

Stay up to date on news & ideas from CIFAR.

Fields marked with an * are required

Je préfère m’inscrire en français (cliquez ici).


Subscribe to our CIFAR newsletters: *

You can unsubscribe from these communications at any time. View our privacy policy.


As a subscriber you will also receive a digital copy of REACH, our annual magazine which highlights our researchers and their breakthroughs with long-form features, interviews and illustrations.


Please provide additional information if you would like to receive a print edition of REACH.


This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.
Accept Learn more

Notifications